Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > News: covid treatment progressing well

<< Previous

Bullboard Posts

Next >>

Post by deanthebeanon Jun 09, 2020 7:51am

148 Views

Post# 31127644

News: covid treatment progressing well

Now the 4th news release in a couple of weeks which touts the progress of their (Salzman's) proprietary R-107 drug in combating covid-19. So far there has been a minimal upwards effect on stock price as kly has remained in the 2.5-3.5 cent range. Can we finally gain some traction and jump up to the 4-5 cent zone? You never know but you can certainly hope. Fingers crossed for all longtime holders.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading